Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 at 12:30 pm
Share
Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the companys chief executive officer and chairman, will deliver a corporate presentation as part of the 40th Annual J.P. Morgan Healthcare Conference. The conference, which will take place January 10-13, 2022, will be conducted in a virtual format. As a centerpiece of the update, Dr. Goldsmith will announce the expansion of the companys development-stage pipeline of RAS(ON) Inhibitors. Additionally, he will outline ongoing development plans for the companys first two RAS(ON) Inhibitor programs: RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C), and provide updates on its two clinical-stage RAS Companion Inhibitors: RMC-4630 (SHP2 inhibitor) and RMC-5552 (mTORC1/4EBP1 inhibitor).
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference